These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36123734)

  • 1. A systematic review of economic evaluations of enzyme replacement therapy in Lysosomal storage diseases.
    Katsigianni EI; Petrou P
    Cost Eff Resour Alloc; 2022 Sep; 20(1):51. PubMed ID: 36123734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.
    Connock M; Burls A; Frew E; Fry-Smith A; Juarez-Garcia A; McCabe C; Wailoo A; Abrams K; Cooper N; Sutton A; O'Hagan A; Moore D
    Health Technol Assess; 2006 Jul; 10(24):iii-iv, ix-136. PubMed ID: 16796930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Systematic Review of the Health Economics of Pompe Disease.
    Schoser B; Hahn A; James E; Gupta D; Gitlin M; Prasad S
    Pharmacoecon Open; 2019 Dec; 3(4):479-493. PubMed ID: 31049836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease.
    Kanters TA; van der Ploeg AT; Kruijshaar ME; Rizopoulos D; Redekop WK; Rutten-van Mӧlken MPMH; Hakkaart-van Roijen L
    Orphanet J Rare Dis; 2017 Dec; 12(1):179. PubMed ID: 29237491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of enzyme replacement therapy for type 1 Gaucher disease.
    van Dussen L; Biegstraaten M; Hollak CE; Dijkgraaf MG
    Orphanet J Rare Dis; 2014 Apr; 9():51. PubMed ID: 24731506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease.
    Kanters TA; Hoogenboom-Plug I; Rutten-Van Mölken MP; Redekop WK; van der Ploeg AT; Hakkaart L
    Orphanet J Rare Dis; 2014 May; 9():75. PubMed ID: 24884717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders.
    Wyatt K; Henley W; Anderson L; Anderson R; Nikolaou V; Stein K; Klinger L; Hughes D; Waldek S; Lachmann R; Mehta A; Vellodi A; Logan S
    Health Technol Assess; 2012; 16(39):1-543. PubMed ID: 23089251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type 1.
    Connock M; Juarez-Garcia A; Frew E; Mans A; Dretzke J; Fry-Smith A; Moore D
    Health Technol Assess; 2006 Jun; 10(20):iii-iv, ix-113. PubMed ID: 16729919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The quality of economic evaluations of ultra-orphan drugs in Europe - a systematic review.
    Schuller Y; Hollak CE; Biegstraaten M
    Orphanet J Rare Dis; 2015 Jul; 10():92. PubMed ID: 26223689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost-effectiveness of enzyme replacement therapy (ERT) for the infantile form of Pompe disease: comparing a high-income country's approach (England) to that of a middle-income one (Colombia).
    Castro-Jaramillo HE
    Rev Salud Publica (Bogota); 2012; 14(1):143-55. PubMed ID: 23250322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses.
    Pouryamout L; Dams J; Wasem J; Dodel R; Neumann A
    Drugs; 2012 Apr; 72(6):789-802. PubMed ID: 22480339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzyme replacement therapy in orphan and ultra-orphan diseases: the limitations of standard economic metrics as exemplified by Fabry-Anderson disease.
    Moore DF; Ries M; Forget EL; Schiffmann R
    Pharmacoeconomics; 2007; 25(3):201-8. PubMed ID: 17335306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation.
    Dundar Y; Bagust A; Dickson R; Dodd S; Green J; Haycox A; Hill R; McLeod C; Walley T
    Health Technol Assess; 2007 Jan; 11(1):1-90. PubMed ID: 17181984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skin Substitutes for Adults With Diabetic Foot Ulcers and Venous Leg Ulcers: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(7):1-165. PubMed ID: 34211616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of lysosomal storage disorders : progress with enzyme replacement therapy.
    Rohrbach M; Clarke JT
    Drugs; 2007; 67(18):2697-716. PubMed ID: 18062719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.